AVBP — ArriVent BioPharma, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1868279 ·
Last close
$27.94
Market Cap
$1.30B
52W High
$32.14
52W Low
$20.72
ADV30
427,478
Next earnings
2026-05-11
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -46,111,000 | -43,320,000 | 349,295,000 | 62,103,000 | 25,315,000 |
| Dec 2025 | 0 | — | -38,823,000 | -35,544,000 | 333,169,000 | 45,540,000 | 25,945,000 |
| Sep 2025 | 0 | — | -38,316,000 | -34,978,000 | 326,555,000 | 112,672,000 | 21,558,000 |
| Jun 2025 | 0 | — | -33,623,000 | -31,399,000 | 269,506,000 | 112,765,000 | 19,636,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-160,588,000
Investing CF
$-71,228,000
Financing CF
$203,063,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-4.24
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-404,641,000
Inventory
—
Receivables
$60,000
ST Investments
$267,281,000
EBIT TTM
$-177,534,000
Pretax Income TTM
$-166,308,000
Interest Exp TTM
—
Analysts
12
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -177,534,000 | -166,308,000 | 333,169,000 | 25,945,000 | — | -160,588,000 |
| Dec 2024 | 0 | -94,308,000 | -80,488,000 | 274,942,000 | 17,288,000 | — | -70,212,000 |
| Dec 2023 | 0 | -74,590,000 | -69,333,000 | 163,098,000 | 316,291,000 | — | -55,842,000 |
| Dec 2022 | 0 | -36,906,000 | -36,906,000 | 182,833,000 | 267,942,000 | — | -43,631,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-3.37
Max Pain — expiry 2026-10-16
max pain strike: $20.00 · spot: $27.94 · call oi: 4,284 · put oi: 124
Expected Move to 2026-10-16:
±$18.95
(67.82%) —
implied range
$8.99 –
$46.89
· ATM straddle on $30.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| HROW | HARROW, INC. | $1.27B | $34.17 | — |
| MLTX | MoonLake Immunotherapeutics | $1.34B | $18.23 | — |
| MPLT | MapLight Therapeutics, Inc. | $1.26B | $29.46 | — |
| WVE | Wave Life Sciences Ltd. | $1.23B | $6.38 | — |
| SEPN | Septerna, Inc. | $1.38B | $30.65 | — |
News headlines (Yahoo Finance, 1h cache)
ArriVent BioPharma Reports First Quarter 2026 Financial Results
2026-05-11 20:01 · Yahoo
A Look At ArriVent BioPharma (AVBP) Valuation After FDA Clears ARR-002 Oncology Candidate
2026-05-10 06:08 · Yahoo
ArriVent Announces IND Clearance for Novel Tetravalent MUC16/NaPi2b Targeting ADC ARR-002 with Initial Focus in Ovarian and Endometrial Cancers
2026-05-07 12:00 · Yahoo
Are You Looking for a Top Momentum Pick? Why ArriVent BioPharma, Inc. (AVBP) is a Great Choice
2026-04-15 16:00 · Yahoo
Are Medical Stocks Lagging AstraZeneca (AZN) This Year?
2026-04-13 13:40 · Yahoo
Wall Street Analysts Think ArriVent BioPharma, Inc. (AVBP) Could Surge 72.44%: Read This Before Placing a Bet
2026-04-06 13:55 · Yahoo
Assessing ArriVent BioPharma (AVBP) Valuation After Recent Share Price Momentum And Pipeline Interest
2026-04-05 01:12 · Yahoo
Are Medical Stocks Lagging ArriVent BioPharma, Inc. (AVBP) This Year?
2026-03-26 13:40 · Yahoo
ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 at the 2026 AACR Annual Meeting
2026-03-17 21:00 · Yahoo
Aarvik Therapeutics Showcases Novel ADC Molecules Based On MUTTA™ and AQUALINK™ Platforms at AACR 2026
2026-03-17 21:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.